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Background. Antigen-specific CTL responses are thought to play a central role in containment of HIV-1 infection, but no
consistent correlation has been found between the magnitude and/or breadth of response and viral load changes during
disease progression. Methods and Findings. We undertook a detailed investigation of longitudinal CTL responses and HIV-1
evolution beginning with primary infection in 11 untreated HLA-A2 positive individuals. A subset of patients developed broad
responses, which selected for consensus B epitope variants in Gag, Pol, and Nef, suggesting CTL-induced adaptation of HIV-1 at
the population level. The patients who developed viral escape mutations and broad autologous CTL responses over time had
a significantly higher increase in viral load during the first year of infection compared to those who did not develop viral
escape mutations. Conclusions. A continuous dynamic development of CTL responses was associated with viral escape from
temporarily effective immune responses. Our results suggest that broad CTL responses often represent footprints left by viral
CTL escape rather than effective immune control, and help explain earlier findings that fail to show an association between
breadth of CTL responses and viral load. Our results also demonstrate that CTL pressures help to maintain certain elements of
consensus viral sequence, which likely represent viral escape from common HLA-restricted CTL responses. The ability of HIV to
evolve to escape CTL responses restricted by a common HLA type highlights the challenges posed to development of an
effective CTL-based vaccine.
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Is Associated with Viral Escape. PLoS ONE 2(2): e225. doi:10.1371/journal.pone.0000225
INTRODUCTION
HIV-1-specific CTLs have a central role in the containment of
viral replication. Reduction in viral load during acute HIV-1
infection is correlated with the appearance of HIV-specific CTLs
[1,2], and studies from the SIV macaque model have shown that
CD8-specific monoclonal antibodies, which block CTL activity,
can eliminate this early viral load reduction [3,4,5]. Also, in
monkeys who received experimental SIV vaccines and sub-
sequently were infected with pathogenic SIV, the frequency of
mutations within CTL epitopes was associated with the level of
viral replication [6].
Many studies have tried to correlate the magnitude and/or
breadth of the CTL response with control of viremia in humans
and for the majority of HLA restriction elements no such simple
relationship exists. In chronic HIV-1 infection both broad and
narrow high frequency CTL responses have been seen in patients
whose CD4+ T cell counts are rapidly declining, or who are at late
stage disease, as well as in asymptomatic patients with stable CD4+
T cell counts and low levels of viremia [7,8,9,10,11]. Still,
immunogenetic studies have clearly shown that certain HLA
alleles, e.g. HLA-B27, -B57 and –B58, are associated with long-
term non-progression (LTNP), while HLA-B35 is associated with
rapid disease progression [11,12,13,14,15,16,17], underscoring
that the efficiency of viral containment varies with CTL specificity.
HIV-1 has been shown to escape host CTL responses through
mutations in CTL epitopes in early infection as well as throughout
the chronic phase of infection [18,19,20,21,22]. The speed at
which a CTL response induces escape is thought to be dependent
on several factors including the potency of the CTL response, how
many nucleotides have to change to create an amino acid
mutation, the effectiveness of the mutation in escaping CTL
responses, and how well the change is accepted structurally and
functionally (i.e. impact on viral fitness). Thus, a CTL response
directed towards an epitope does not always lead to escape
[23,24,25]. Of particular interest is the finding that delayed
emergence of CTL escape mutants within an immunodominant
HLA-B27-restricted epitope in Gag can lead to an increase in viral
load and outgrowth of virus carrying escape mutations [7,8,26].
The CTL selection pressure exerted by HLA-B27 may not be
greater than that exerted by other HLA restriction elements early
in disease. Nevertheless, the protective effect of a delayed
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the frequent occurrence of compensatory mutations, may be
related to the finding that escape, if it does occur, is associated with
a viral fitness cost greater than that related to escape mutations in
most other epitopes [27]. An additional case report showed that
a combination of CTL escape and lost HIV-1-specific CD4+ T
cell help can precede viral breakthrough in early chronic infection
[28]. Thus, an effective, but narrow immunodominant CTL
response against an epitopic region can persist until late in the
natural history of HIV-1 disease and appears to be associated with
control of viral replication.
HIV-1 continuously adapts to HLA-restricted CTL responses at
the population level resulting in ‘‘HLA footprints’’
[29,30,31,32,33]. Several sites have been associated with positive
selection by certain HLA alleles, while others are negatively
associated with a different set of common HLA alleles. These
associations reflect previous adaptation of the virus to the human
host. After transmission of a CTL escape variant to a new host
who does not carry the restrictive HLA allele, some variants are
maintained while others revert, suggesting that those which revert
are associated with a decrease in viral fitness [21,34,35]. Thus, the
accumulation of mutations within the HIV-1 genome is not
infinite [21,36,37,38]. The stability of an escape mutation
combined with the rate at which mutations are induced has
important implications for vaccine development. Although a sub-
stantial number of studies have described viral escape, they mostly
rely on case reports, a very limited number of patients and/or
sequences, or are cross-sectional studies. Little is known about the
early hierarchy in targeting CTL epitopes and relative immuno-
dominance, the timing of escape mutations, and how efficient
novel CTL responses can be generated towards epitope variants in
acutely infected humans. Still, it is essential to evaluate the
specificity and characteristics of immune responses that are able to
control viral replication for the development of preventive or
therapeutic vaccination.
To address these questions we undertook a comprehensive
longitudinal study of eleven untreated individuals who presented
with primary HIV-1 infection. We observed the complex
interactions between an evolving viral population and the
development of autologous cellular immune responses against
optimally defined HLA-A2-restricted epitopes situated in Gag,
Pol, Env, and Nef. We also investigated the interactions between
CTL responses restricted by different HLA alleles in overlapping
and flanking epitopes in the p17 region of HIV-Gag and HIV-Nef.
We provide clear phylogenetic and functional evidence of HIV-1
CTL escape within targeted epitopes in HIV-Gag, Nef, and Pol.
In two independent examples we show that CTL responses
directed at variant epitope sequences in HIV-Gag and –Pol caused
selection of a consensus B-like sequence. We also show that the
lack of responses to the HIV-Nef epitope in primary infection were
associated with a pre-existing CTL escape variant that was
probably present in the transmitted virus, suggesting adaptation of
HIV-1 to HLA-A2-restricted CTL responses at a population level.
Finally, our results identify a paradox in which broad CTL
responses in early infection, when linked to escape mutations, were
associated with an increased HIV-1 load. Although early HLA-
restricted responses may have helped limit viral load, subsequent
CTL escape effectively abrogated the effects of the CTL response.
The development of new CTL responses resulted in broader
responses as the earlier temporarily effective responses persisted as
immunological footprints. This has important clinical implications
for the manipulation of CTL responses by therapeutic immuni-
zation. Great care at the epitope specific level may be needed if
selective manipulation of CTL responses is to be beneficial.
METHODS
Subjects
Eleven untreated HLA-A2-positive subjects from the OPTIONS
cohort at the Positive Health Program, University of California,
San Francisco were identified for the study (Table 1). Criteria for
primary and early HIV-1 infection in the cohort have been
presented previously [39]. The male subjects were infected
through homosexual contact with HIV-1 strains belonging to
subtype B. Our inclusion criteria were: (i) HLA-A2-positive, (ii)
treatment naı ¨ve throughout study period, (iii) longitudinal samples
available for a minimum of one year, and (iv) viral loads
.50 copies/ml. A control group of 12 HLA-A2-negative subjects
from the cohort was also identified (Table 1). The study was
approved by the UCSF Institutional Review Board, and all
subjects provided written informed consent.
PBMC and plasma samples were obtained from the HLA-A2-
positive subjects approximately every 24-weeks from primary
HIV-1 infection. An initial sample was available at an estimated
median of 11 weeks (interquartile range: 10–13) from infection
(Table 1), a timepoint after the initial two months in which HIV-1
infected subjects have been shown to reach a steady viral load
[40]. The date of HIV-1 infection was estimated based on prior
data on the median time from exposure to acute retroviral
syndrome or an indeterminate HIV-1 antibody test [41], the mid-
point between last negative and first positive HIV-1 antibody tests,
or the level of a less sensitive HIV-1 antibody test if the optical
density was between 0.5 and 1.0, a range in which there has been
shown to be a linear relationship between the less sensitive
antibody results and the days since seroconversion [42]. The first
plasma sample was obtained after peak viremia, and the median
plasma viral load was 2,300 copies/ml (interquartile range: 1,400
to 35,500 copies/ml).
HIV-1 quantification, sequencing and cloning
Plasma HIV RNA levels were determined by Bayer’s branched
DNA technique (Bayer Diagnostics, Emeryville, California, USA).
Plasma HIV RNA was extracted, reverse transcribed and
amplified using both population based sequencing and cloning
[43,44]. Our primers were selected to amplify HIV-1 gag (HXB2
nt position 790–1431), pol (HXB2 nt position 2147–3462), or nef
(HXB2 nt position 8774–9540) (Table S1).
In brief, viral RNA was isolated from plasma using DynabeadsH
Oligo(dT)25 (Invitrogen Corporation, Dynal Biotech, Oslo, Nor-
way) and HIV-1 genes were reverse transcribed and amplified
using the gene specific primers as recommended by the
manufacturers of the Titan One Tube RT-PCR kit (Roche
Diagnostics GmbH, Roche Applied Science, Penzberg, Germany).
Second-round PCR reactions were carried out using the
Expanded High Fidelity enzyme blend (Roche Diagnostics
GmbH).
To decrease the number of possible PCR-introduced errors
and ensure a high input of virus strains into the PCR, several
amplifications were done in parallel and were pooled afterward
[45]. In samples with low viral load, several individual PCR
amplicons were sequenced. The PCR product was purified
using ExoSAP-ITH (USB Corporation, Cleaveland, OH, USA),
sequenced directly or cloned (TOPO TA cloning kit; Invitro-
gen, Carlsbad, CA, USA). Plasmid DNA was purified using
QIAprep Spin (QIAGEN, Valencia, CA, USA) and sequenced.
Sequences were imported and manually edited using Se-
quencher software (Gene Codes Corporation, Ann Arbor, MI,
USA).
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A total of 20 HLA-A2-restricted epitopes in HIV-1 Gag, Pol, Env
and Nef were identified in the Los Alamos HIV Molecular
Immunology Compendium (Table 2) [46]. Furthermore, our
sequencing data disclosed several autologous viral epitope variants
in Gag, Pol (except RT 309-319) and Nef, and peptides
corresponding to both the autologous and all consensus B epitope
sequences [47] were synthesized.
Phylogenetic and selection analysis
The aligned sequences, obtained by direct sequencing and cloning,
were analyzed together with reference sequences from the HIV
sequence database (http://hiv-web.lanl.gov/) using MEGA to
exclude the possibility of contamination. Viral variability and
evolution were determined within the HLA-A2-restricted epitopes
to reveal potential CTL escape (n=15 epitopes). Mutations within
epitopes or flanking regions were identified. The sequences have
been submitted to GenBank (GenBank accession numbers:
EF396480–EF396891).
Phylogenetic trees were constructed from sequenced clones
obtained for patients OP177 (Nef), OP428 (Gag and Pol), and
OP599 (Gag) by maximum likelihood using PAUP* 4.0b10 [48].
The GTR+c model of nucleotide substitution was used with model
parameters estimated on an initial neighbour-joining tree. A
heuristic search was then performed using SPR branch swapping.
The substitution model parameters were re-estimated and the
heuristic search repeated. Non-parametric bootstrap support
estimates were obtained using 2000 replicates under neighbour-
joining using the maximum likelihood substitution model.
Natural selection of specific amino acid sites in Gag, Nef and
Pol were examined using the codeml program from the PAML
package (version 3.13) [49]. This program works by assessing the
fit of the data to various models of codon evolution while taking
into account the phylogenetic relationships of the sequences. We
used ‘‘NS-sites’’ models that allow the nonsynonymous/synony-
mous (dN/dS) ratio (v) to vary among sites [50,51] and examined
six models: M0, considering one ratio for all sites; M1a, near
neutrality (two classes of sites with v,1 and =1); M2a, positive
selection (three classes of sites v,1, =1 and .1); M3, discrete v
categories; M7, discrete beta-distributed ratios; and M8, beta-
distributed ratios with v.1. Nested sets of these models [(M0,
M1a, M2a, M3) and (M7, M8)] were examined using hierarchical
likelihood ratio tests [52] and amino acid sites with Bayesian
posterior dN/dS ratios reflecting positive selection were reported.
Immunological measurements
The intracellular cytokine flow cytometry (CFC) assay was
performed using frozen PBMC samples as previously described
[53]. Briefly, cells were thawed, stimulated with peptides (2 mg/ml)
and incubated overnight. The PBMC were stained with Pacific
Blue (PB)-conjugated anti-CD4, and Phycoerythrin-Cy7 (PE-Cy7)-
conjugated anti-CD8 (BD Biosciences, San Jose, CA, USA) for
20 minutes at 4uC. Simultaneous staining with 1 mg/ml ethidium
Table 1. HLA-A2-positive and HLA-A2-negative patient characteristics.
..................................................................................................................................................
Patient Sex Week
A HLA-A allele HLA-B allele Viral Load (copies/ml) CD4 (cells/mm
3) CD8 (cells/mm
3)
OP-177
B Male 10 02 31 15 40 8,805 360 342
OP-428
B Male 15 01 02 08 08 2,340 1,260 1,092
OP-454 Male 10 01 02 51 57 151 528 560
OP-474
C Male 10 02 02 40 42 1,420 493 629
OP-478
C Male 12 02 24 44 51 265 594 1,122
OP-488 Male 13 02 24 27 50 2,249 748 1 078
OP-506 Male 11 02 03 08 35 151,107 286 494
OP-539
C Male 6 02 03 44 47 58,189 588 945
OP-581 Male 11 01 02 27 51 41,605 616 1,100
OP-583 Male 9 02 31 14 40 48,413 495 765
OP-599
B Male 14 02 02 13 51 1,451 558 738
HLA-A2-Negative
OP-138 Female 29 03 32 27 35 16,460 585 442
OP-430 Male 38 03 03 44 51 36,854 240 1,776
OP-443 Male 10 01 29 35 81 18,218 714 1,176
OP-470 Male 20 11 68 35 40 33,893 462 420
OP-565 Male 25 01 24 08 50 159,750 465 825
OP-626 Male 10 03 30 35 49 59,035 888 768
OP-683 Male 10 26 66 35 41 80,599 528 672
OP-700 Male 26 01 11 07 40 32,902 551 931
OP-722 Male 30 03 11 07 40 124,070 522 1,080
OP-745 Male 10 11 24 13 48 36,254 560 1,140
OP-791 Male 10 01 24 40 57 4,973 570 665
OP-842 Male 3 03 25 40 55 6,876 560 496
AEstimated week from infection.
BSubject who developed broad HLA-A2 restricted responses.
CSubjects who developed narrow HLA-A2-restricted CTL responses against
SL9, after primary infection.
doi:10.1371/journal.pone.0000225.t001
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cells were exposed to fluorescent light and fixed in 4% para-
formaldehyde. The cells were permeabilized using FACS Perm
solution (BD Biosciences), and stained using PE-Texas Red (ECD)
conjugated CD3 (Beckman Coulter, Miami, FL, USA), fluorescein
isothiocyanate (FITC)-conjugated anti-TNF-a, R-phycoerythrin
(PE)-conjugated anti-IL-2, and allophycocyanin (APC)-conjugated
anti-IFN-c (BD Biosciences). The cells were fixed in 1%
paraformaldehyde, and data was collected on a BD LSR-II using
FACS DIVA software (BD Biosciences).
The gating strategy for all samples was to set a gate on the
unstimulated control such that CD3+CD8+CD4-T cells were
negative for IFN-c and TNF-a. The background signal was
a median of 0.07% (interquartile range: 0.03–0.18%) of the IFN-c
and TNF-a-producing CD8+ T cells and was subtracted in each
experiment. A sample was considered positive (above the cutoff)
when the response was at least twice the experimental background
signal.
RESULTS
Previous studies of primary HIV-1 infection have shown limited
responsiveness to several HLA-A2-restricted CTL epitopes
[54,55,56,57], even though responses against the HIV Gag 77-
85 (SL9,
77SLYNTVATL
85) epitope becomes immunodominant
in chronic infection [55,56,58]. However, the timing of the onset
of HLA-A2-restricted responses, their impact on viral evolution,
and the potential efficiency of subsequent CTL responses
generated towards autologous epitope variants are largely un-
known. To address these questions, we identified eleven HLA-A2-
positive patients in primary HIV-1 infection in the OPTIONS
cohort according to the criteria described [39]; all had detectable
viral loads (.50 copies/ml) and none received anti-retroviral
therapy throughout the study period (Table 1). We furthermore
included a control group of twelve drug-naı ¨ve, newly infected,
HLA-A2-negative patients who also fulfilled the above viral load
criteria (Table 1).
Striking paucity of HLA-A2-restricted HIV-1 specific
CTL responses at primary infection
We tested PBMC from our eleven HLA-A2-positive patients for
secretion of IFN-gamma and TNF-alpha in the CFC assay using
a panel of 20 HLA-A2-restricted peptides, which corresponded to
autologous and consensus B epitope [46] variants from HIV-Gag,
Pol, Env and Nef. At the first time-point tested, a median of 11
weeks (range 6 to 15 weeks) after HIV-1 infection, only two
(OP599 and OP177) of the eleven patients were found to have
HIV-specific HLA-A2 restricted CTL responses (Figure 1A).
OP599 recognized two epitopes, one in Gag and the other in Env
(SL9, and Env 813-22), and OP177 responded to one epitope in
Nef (Nef 83-91, AL9), responses that showed up at week 14 and 13
post-infection, respectively for each patient. None of the targeted
epitopes were located in HIV-Pol (protease and RT).
Development of broad HLA-A2-restricted responses
is associated with viral escape and an increased viral
load during the first year of infection
During the study period (range: 1–3 years; median: 2 years) there
was a significant increase in the frequency of HLA-A2-restricted
CTL responses in the subjects expressing HLA-A2 (Figure 2A,
Paired T-test, p=0.03). A total of 6/11 (55%) patients (Table 1)
developed responses to one or more HIV-1 epitopes (Figure 1B,
2A). This response frequency is comparable to that found in
chronic untreated patients (ACK, unpublished data). Two of these
patients had HIV-1 specific CTL responses in primary infection
and developed additional responses towards SL9, Nef 180-189
(VL10), RT 181-189, and RT 309-317 (IV9) (OP177) and Gag
(p1) 433-442, and RT181-189 (OP599) (Figure 1C). Of the four
patients who only developed responses after primary infection, all
recognized the SL9 epitope in the HIV-Gag p17 region and one of
these (OP428) also developed responses towards Gag (p1) 433-442,
Env 121-129, and RT 33-41 (Figure 1C).
Patients with broad CTL responses, OP177, OP428, and
OP599, targeted four to five HLA-A2-restricted epitopes and our
analysis showed that several of these epitopes over time developed
mutations associated with CTL escape (described in detail below).
This broadening of HLA-A2-restrcited responses during the study-
period was associated with an increase in plasma viral load during
the first year of infection (Figure 2B, 2C), as these three patients
had a viral load increase of .0.5 log10, compared to only one of
seven patients with no, or only SL9-specific, CTL responses
(Fisher’s exact test, p=0.03). One HLA-A2-positive patient,
OP478, identified as being superinfected with a second viral
variant during the first year of infection (F.M.H., unpublished
data) was excluded from this analysis. While the viral load
increased more in the patients who developed broad CTL
responses, at year one the average viral loads were similar
(Figure 2C). Also, after year one the viral load remained stable for
the duration of the study as shown in Figure 3. Thus the initial
greater increase in viral loads did not lead to worse control of viral
replication but to viral replication levels that were more similar to
the rest of the group.
The limited reduction in viremia during year one in some of the
subjects (Figure 2B) may reflect a slow ongoing reduction in viral
Table 2. HLA-A2 restricted epitopes in HIV-Gag, -Env, -Nef and
–Pol.
......................................................................
Name
Sequence
(Consesnsus B)
Nucleotide position
(HXB2)
Gag 77-85 (SL9) SLYNTVATL 1017R1043
Gag 151-159 TLNAWVKVV 1239R1265
Gag 363-370 VLAEAMSQV 1872R1898
Gag 433-442 FLGKIWPSHK 2086R2115
Env 121-129 KLTPLCVTL 6583R6609
Env 192-200 RLISCNTSV 6796R6822
Env 311-320 RGPGRAFYTT 7153R7182
Env 813-822 SLLNATAIAV 8659R8688
Nef 83-91 (AL9) AAVDLSHFL 9041R9067
Nef 137-145 LTFGWCFKL 9205R9231
Nef 180-189 (VL10) VLVWRFDSRL 9331R9361
PR 45-54 KMIGGIGGFI 2384R2413
PR 76-84 LVGPTPVNI 2477R2503
RT 3-12 SPIETVPVKL 2555R2584
RT 33-41 ALVEICTEM 2645R2671
RT 108-118 VLDVGDAYFSV 2871R2903
RT 179-87 (VL9) VIYQYMDDL 3083R3109
RT 181-189 YQYMDDLYV 3089R3115
RT 209-220 LLRWGLTTPDKK 3173R3208
RT 309-317 (IV9) ILKEPVHGV 3473R3499
doi:10.1371/journal.pone.0000225.t002
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PLoS ONE | www.plosone.org 4 February 2007 | Issue 2 | e225density, under immunological control [40]. The outlier in this
group, OP454, had a 1.7 log10 increase in viral load during the
first year (151 to 7,261 copies/ml), had the lowest initial viral load
of all patients (Figure 3), and did not develop any HLA-A2-
restricted CTL responses during the three years studied. This
patient was HLA-A1, B57, and B51 positive and may have had
strong CTL responses restricted by any of these HLA molecules,
undetected in our analysis. In a plasma sequence obtained at
estimated week 106 from infection we did not detect any
mutations within epitopes in HIV-Nef and HIV-Pol, but the
I147L mutation located within the HLA-B57-restricted
147ISPRTLNAW
155 (IW9) epitope in HIV-Gag was present,
although not in association with the A146P mutation known to
alter antigen processing [59]. In addition, the HIV-Gag sequence
Figure 1. Continuous development of HLA-A2-restricted CTL responses. (A) At study entry only two of eleven patients (OP177 and OP599) showed
detectable responses to three of the 20 HLA-A2-restricted epitopes tested. * Both epitopes were recognized by OP177. (B) At early chronic infection
(week 48–144 of follow-up) most patients had developed a response against the Gag 77-85 (SL9) epitope. (C) Three of the eleven subjects (OP177,
OP428, and OP599) developed broad HLA-A2-restricted CTL responses targeting four to five epitopes. The magnitude of the CD8+ T cell responses is
given as the percentage of cells producing IFN-c and TNF-a after withdrawing the experimental background.
doi:10.1371/journal.pone.0000225.g001
CTL-Driven HIV Evolution
PLoS ONE | www.plosone.org 5 February 2007 | Issue 2 | e225contained the G79F mutation located at the anchor position of the
HLA-A1-restricted epitope
71GSEELRSLY
79, which we show to
have conferred viral escape in OP428.
The interplay of host CTL responses and viral
evolution in HIV-Nef
In our longitudinal sequence analysis we identified several
mutations in and around epitopes targeted by the HLA-A2-
restricted CTL responses in subjects OP177 (Nef), OP428 (Gag
and Pol), and OP599 (Gag) and next examined the interaction
between virus evolution and epitope-specific CTL responses. We
first analyzed the interactions between the high-magnitude HLA-
A2-restricted AL9 specific CTL response detected at baseline in
subject OP177 (Figure 1C), sequence changes and viral load. Our
sequence analysis showed that patient OP177 at the earliest
sample time point (week 10) carried virus with two different
versions of the AL9 epitope,
83AAVDLSHFL
91 [60]. The major
population (11/16 clones) was identical to the consensus B
sequence (AAVDLSHFL) while the minor population (5/16
clones) contained a L87I substitution (AAVDISHFL) (Table 3).
At 13 weeks post-infection, we could detect a potent CTL response
against the subtype B consensus epitope sequence, while a less
intense CTL response targeted the L87I epitope variant,
concurrent with the L87I sequence then dominating the viral
population. By week 37 none of 17 clones carried the consensus B
sequence and by week 61 the majority of the clones (86%) carried
the L87I substitution. Despite a .33 fold increase in viral load, the
CTL response against the L87I epitope variant only increased
two-fold and the response toward the consensus B specific CTL
response decreased substantially indicating that the L87I-specific
CTL were less efficient in controlling viral load. After week 61,
further mutations were seen within the epitope; some linked with
the L87I mutation, others not. In the last sample, drawn at week
158, the major population (13/14 clones) carried two new
mutations, A83G and V85L, while the position 87 had reverted
back to a wild type leucine, and new, less prevalent HLA-A2-
restricted CTL responses towards these variants could be detected.
To evaluate the impact of these epitope changes on the
evolution of the viral population in OP177 we superimposed the
changes on a maximum-likelihood phylogenetic tree created using
the full-length nef sequences (Figure 4). Furthermore, using an
independent phylogenetic method, codeml [49], we identified 20
amino acid positions undergoing positive selection within the Nef
region. Nine of the positions (22, 50, 64, 83, 85, 87, 91, 98, and
184) fell within known CTL epitopes, restricted by the patients
HLA alleles (A2, A3, B15, and B40). These analyses confirmed
that several of the amino acid positions in the AL9 epitope (83, 85,
87 and 91), were under positive selective pressure, presumably
caused by the HLA-A2-restricted CTL response (Figure 4). To
Figure 2. Broad HLA-A2-restricted CTL responses are associated with an early increase of viral load (A) The number of targeted epitopes in
primary and early chronic infection increased significantly during the study-period (Paired T-test, p=0.03). While only one patient recognized 2
epitopes in primary infection, three targeted at least 4 epitopes, situated in HIV-Gag, Env, Nef and Pol, in early chronic infection. (B) All three patients
who targeted multiple epitopes (open circles) had a viral load increase .0.5 log10 during the first year of infection, compared to just one of seven
patients with narrow or absent HLA-A2-restricted responses (closed circles) (Fisher’s exact test, p=0.03). Patient OP478, identified as being
superinfected during the first year of infection, was excluded from this analysis. (C) While the viral load increased more in the group with broad HLA-
A2-restricted responses during the first year of infection (open circles), the absolute viral load increase was not significant in the group during year
one (Paired T-test, p=0.15).
doi:10.1371/journal.pone.0000225.g002
CTL-Driven HIV Evolution
PLoS ONE | www.plosone.org 6 February 2007 | Issue 2 | e225Figure 3. Longitudinal viral load measures in HLA-A2-positive subjects followed for more than one year (i.e. excluding OP474 and OP506).
During the study period three subjects (OP177, OP428, and OP599) developed multiple HLA-A2-restricted CTL responses, which selected for
mutations associated with viral escape within targeted epitopes. The additional six subjects followed for more than a year did not develop any HLA-
A2-restricted responses or only against the SL9 epitope in HIV-Gag (OP478, and OP539).
doi:10.1371/journal.pone.0000225.g003
CTL-Driven HIV Evolution
PLoS ONE | www.plosone.org 7 February 2007 | Issue 2 | e225evaluate the potential contribution of additional CTL responses
against the region we tested all the appropriate autologous peptide
variants of eight known CTL epitopes, and also included six
peptides from the HIV-1 group M consensus Nef (15-mer)
peptides set (NIH AIDS Research and Reference Program,
Division of AIDS, NIAID, NIH) spanning five other positions,
in a sample obtained at estimated week 158 from infection. CTL
responses were identified against three epitopes, containing
positions E98D and R184K (Table 3). An HLA-B40 restricted
response was detected against the Nef 92-100 (
92KEKG-
GLEGL
100, KL9) epitope, adjacent to the HLA-A2 restricted
AL9 epitope. A high frequency (1.41%) of the CD8 T-cells
targeted the wild-type variant and only a minority (0.32%) were
against the emerging E98D containing variant, which was found at
low frequency in the clones from weeks 109 and 158. Overlapping
HLA-A2 (
180VLEWRFDSRL
189, VL10) and HLA-B15 (Nef 183-
191,
183WRFDSRLAF
191, WF9) restricted CTL responses differ-
entially recognized the 184K mutant. The HLA-A2-restricted
VL10 primarily recognized the wild-type version of the epitope
while a potent HLA-B15 restricted response was directed against
the emerging 184K variant of the epitope (1.28%), but did not
recognize the wild-type version. In summary, we could confirm
that the adjacent positions 83, 85, 87, 91, and 98 all were under
pressure by flanking HLA-A2 and HLA-B40 restricted CTL
responses and that position 184 fell under two overlapping CTL
responses restricted by HLA-A2 and HLA-B15. Also, early escape
from the AL9 CTL response occurred simultaneously with a sharp
increase in viremia. Although we found a clear association
between CTL responses and viral evolution for six of the positions
under positive selection, no such association was found for the
other 14 positions. As we were unable to obtain and test a sample
drawn earlier than week 158 we cannot exclude the presence of
additional CTL responses at earlier time-points. However, the
majority of the sequence changes were seen at the later time-
points, in clones obtained at week 109 and 158, so it is unlikely
that we would have failed to detect the presence of responses in
Table 3. Early viral escape driven by an HLA-A2-restricted response against HIV-Nef. The interactions between viral evolution
(within all defined targeted epitopes), anti-HIV-specific CTL responses, and viral load, was followed in subject OP177.
..................................................................................................................................................
Week
A HIV-Nef Sequence
B Clones
C
CD8+ T cell responses
(% IFN-c and TNF-a)
D Viral
Load
HLA-A2 HLA-B40 HLA-A2 HLA-B15
AL9 KL9 VL10 WF9
83AAVDLSHFLKEKGGLEGL
100 180VLEWRFDSRLAF
191 AL9 KL9 VL10 WF9
10 ------------------ ------------ 8/16 8,805
------------------ --------S--- 2/16
------------------ -----------L 1/16
----I------------- ------------ 5/16
13 ------------------ ------------ 8/26 1.10 17,260
----I------------- ------------ 15/26 0.14
----I------------- ------G----- 1/26 0.14
----I------------- -----------C 1/26 0.14
----I------------- -----------L 1/26 0.14
37 ----I------------- ------------ 8/17 21,600
--------I--------- ------------ 9/17
61 ----I------------- ------------ 12/14 0.31 295,000
----IR------------ ------------ 1/14
--------I--------- ------------ 1/14
109 --L-I------------- ------------ 7/13 0.10 164,776
--L-I--L---------- ------------ 1/13
--L--------------- ------------ 1/13
G-L--------------- ------------ 2/13 0.06
G-L------------D-- ------------ 1/13 0.06
K-L------------D-- ------------ 1/13
158 --L-I------------- ------------ 1/14 0.13 1.41 0.25 0.00 270,035
G-L--------------- ------------ 6/14 0.19 1.41 0.25 0.00
G-L--------------- ----K------- 4/14 0.19 1.41 0.19 1.28
G-L------------D-- ------------ 2/14 0.19 0.32 0.25 0.00
G-L-------------E- ------------ 1/14 0.19 0.25 0.00
AEstimated week from infection.
B The HXB2 sequence is given as a reference with the HLA-A2 restricted epitopes AL9 and VL10 indicated with an unbroken line in bold
face letters, the HLA-B40 restricted epitope KL9 with a dotted line, and the HLA-B15 restricted WF9 epitope with double lines.
C The frequency of each clone is given as
a number of the total number of clones sequenced with the major autologous sequence at each time-point given in bold face letters.
DThe autologous CTL responses
are given for each peptide tested. The viral variant that generates the strongest CTL response at each time-point are indicated in bold face letters.
doi:10.1371/journal.pone.0000225.t003
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CTL-Driven HIV Evolution
PLoS ONE | www.plosone.org 8 February 2007 | Issue 2 | e225Figure 4. Phylogenetic tree illustrating viral evolution of the HIV-nef region (HXB2 coordinates 8774–9540) in subject OP177. Positive selection
occurs from the HLA-A2-restricted CTL response (AL9,
83AAVDLSHFL
91) at positions 83, 85, 87 and 91 and the variation at these sites are shown in
color on the tree and branches (amino acid positions identical to the consensus B sequence are shown in blue and variations in red) as well as
sporadic variation elsewhere in the epitope (shown in green). The patient’s virus evolves from the consensus 83A, 85 V, 87L/I, 91L (all blue except 87I
which is red) to 83G (red), 85L (red), 87L (blue), 91L (blue) over approximately three years during which various epitope variants with single, or linked
mutations occur in the population (83K, 87I, 91I, shown in red). Of note is the temporary predominance of the 87I mutation, which is lost shortly after
the 85L mutation develop. An X at the end of the clone name refers to changes in other epitopes; green X=KL9 epitope, E98D, green XX=KL9
epitope, G99E, red X=VL9 epitope and overlapping WF9 epitope, R185K, blue X=sporadic changes in WF9 epitope (Table 3). Amino acid numbering
corresponds to HXB2 Gag. Scale bars signify substitutions/site. w: corresponds to estimated week from infection (e.g. a clone named 177_w13 are
obtained from a plasma sample drawn at week 13).
doi:10.1371/journal.pone.0000225.g004
CTL-Driven HIV Evolution
PLoS ONE | www.plosone.org 9 February 2007 | Issue 2 | e225our sample from week 158. This notion is supported by the fact
that we could still detect HLA-A2-restricted CTL responses
against the initial wild-type AL9 epitope (0.20% IFN-c producing
CD8+ T cells), a sequence that had not been detected since week
13. Instead, as several of the amino acid changes (50, 133, 174,
176) were associated with reversion toward a consensus-B like viral
sequence, it is possible that many amino-acid changes throughout
the Nef sequence were selected for because they conferred an
increase in viral fitness.
Viral adaptation induced by HLA-A2-restricted Nef-
specific CTL
Patient OP177 was one of two HLA-A2-positive patients studied
who had a virus identical to the consensus B sequence within the
AL9 epitope in early infection, and the only one who developed
CTL responses against the epitope (Table 4). Baseline virus
sequences from the other eight HLA-A2-positive patients all
carried glycine in position 83, which in seven of the patients was
linked to a leucine, phenylalanine or arginine in position 85
(Table 4). To evaluate if the changes could be due to very early
CTL escape not detected in our baseline samples, we obtained
viral sequences from twelve matched HLA-A2-negative subjects
identified at primary infection (Table 1). Similar to the HLA-A2-
positive subjects, eleven of these twelve had a glycine in position 83
and/or leucine or phenylalanine in position 85 (Table 4). When
compared to sequences obtained after a mean of 96 weeks of
follow-up, none of HLA-A2-positive (except OP177) or HLA-A2-
negative patients showed any sign of mutations or reversions
within the epitope except for patient OP478 who was identified as
being superinfected with a second viral variant during the first year
of infection (F.M.H., unpublished data). None of the HLA-A2-
positive subjects who acquired a variant of the epitope at primary
HIV-1 infection were able to generate a CTL response against
autologous virus during the study period. Furthermore, in the
absence of an autologous Nef-specific CTL response, the
mutations persisted in both HLA-A2-positive and HLA-A2-
negative subjects for years. Our results suggest that the selective
pressure induced by an HLA-A2-restricted early CTL response
towards the consensus B version of the AL9 epitope has induced
a change in the epitope that has become fixed in the majority of
circulating HIV-1 subtype B viruses, possibly because no, or only
negligible, fitness cost is associated with the change. This is a novel
example of viral adaptation to an HLA-A2-restricted CTL
response.
HLA-A1 and -A2-restricted CTL responses select for
dual escape mutation
Patient OP428, the third patient who developed a broad HLA-A2-
restricted response during early chronic infection, also had an
intricate interaction between cellular immune responses restricted
by several HLA-alleles and viral evolution (Table 5). We detected
an HLA-A2-restricted CTL response against the major autolo-
gous, Gag SL9 epitope variant
77SLYNTIATL
85 (82I) by week 39,
and by week 63 several clones had developed an additional Y79F
mutation in position three of the epitope (
77SLFNTIATL
85). We
measured the cellular immune response against the two viral
variants and found the 79F mutant to elicit a 50% lower
magnitude and a log lower functional avidity CTL response than
the initial V82I variant (Figure 5). By week 88, when 42% of the
clones contained the 79F mutation, the magnitude and functional
avidity of CTL recognition of the 79F82I variant had increased
and was similar to the recognition of the initial SL9-82I variant
indicating sequential maturation of the mutant-specific response
(Figure 5). Still, by weeks 139 and 156 the vast majority of the viral
clones contained the Y79F mutation. Phylogenetic analysis
showed positive selection of the Y79F substitution as well as an
E62G/V/A change upstream of the SL9 epitope. When we
analyzed the viral population in the context of the phylogenetic
tree (Figure 6), the Y79F mutant was seen in combination with
both 62E and 62G at week 63 from infection. However, this
combination did not propagate very successfully and at later time
points the virus population primarily carried a combination of the
62A and 79F mutations, coinciding with substantial increases in
viral load (Table 5). Structural analysis of the p17 monomer
showed that the side-chain of the amino acid in position 62
interacts with the side-chain of the amino acid in position 79
(A.K.N.I., unpublished data, and [61]). The 62A mutation may
thus be a compensatory mutation reducing, or eliminating, any
fitness cost associated with the Y79F escape mutation and the
potential immunologic impact imposed by the developing HLA-
A2-restricted CTL response against the 79F variant epitope. HIV-
Table 4. Signature pattern and viral evolution within the HLA-
A2-restricted AL9 epitope.
......................................................................
Subject Epitope Sequence
Baseline Follow up
A
AAVDLSHFL
B AAVDLSHFL
B
HLA-A2-Positive
OP177 --------- G-L------
OP428 ---------
C ---------
OP474 G-------- n.a.
OP478 G-------- --R------
D
OP454 n.a. G-L------
OP488 G-L------ G-L------
OP506 G-L------ n.a.
OP539 G-L------ G-L------
OP581 G-L------ G-L------
OP583 G-R------ G-R------
OP599 G-L------ G-L------
HLA-A2-Negative
OP138 G-L------ G-L------
OP430 G-L------ G-L------
OP443 --I------ --I------
OP470 G-L------ G-L------
OP565 --------- ---------
OP626 G-L------ G-L------
OP683 G-F---F-- G-F---F--
OP700 G-L------ G-L------
OP722 G-L------ G-L------
OP745 G-L------ G-L------
OP791 --L------ --L------
OP842 --L------ n.a.
AThe follow up sequence was available from a mean of 96 weeks from base-line
(range: 72–144 weeks).
BThe Consensus B sequence of the AL9 epitope is given
as a reference for amino acid position 83-91.
CSequence obtained at estimated
week 39 from infection.
DViral evolution due to a confirmed case of HIV
superinfection within the first year of infection (F.M.H., unpublished data).
Dashes represent identity with the reference sequence.
doi:10.1371/journal.pone.0000225.t004
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CTL-Driven HIV Evolution
PLoS ONE | www.plosone.org 10 February 2007 | Issue 2 | e2251 subtype B virus rarely carries an alanine in position 62 (,1%),
but the frequency is increased in combination with 79F (5%) [62].
Additional amino acid changes were detected close to positions
Y79F and V82I in this epitope rich region of p17 Gag. We
compared defined epitopes with OP428’s HLA type (A1, A2 and
B8), and found three additional epitopes to which the patient could
respond. One was an HLA-A1 restricted epitope spanning Gag
71-79 (GY9), and two were B8 restricted epitopes spanning Gag
74-82 (EV9) and Gag 93-101 (EL9). While we detected no CTL
response against the EV9 epitope, responses could be found
against both the GY9 and EL9 epitope at week 63 (Table 5).
Approximately 0.8% of the patients CTLs targeted the GY index
epitope,
71GSEELRSLY
79, while there was no recognition of the
Y79F variant epitope. Neither did the patient develop any
response targeting the Y79F variant epitope as measured in
samples obtained at weeks 88 and 139 (data not shown). The 79F
substitution is situated in the anchor position of the HLA-A1-
restricted epitope, and most likely negatively affects binding to the
HLA molecule. In comparison to the HLA-A2-restricted CTL
responses against the autologous SL9 epitope, the functional
Table 5. Viral escape from an intricate HIV-Gag specific CTL response restricted by three HLA-alleles followed in patient OP428.
..................................................................................................................................................
Week
A HIV-Gag p17 Sequence
B Clones
C CD8+ T cell responses (% IFN-c and TNF-a)
D Viral Load
(copies/ml)
HLA-A1 HLA-A2 HLA-B8
GY9 SL9 EL9
71GSEEL RSLYNTVATL YCVHQRIEVK DTKEAL
101 SL9 GY9 EL9
15 ----- ------I--- ---------- ------ 15/16 0.00 2,340
----- ------I--- ---------- ---G-- 1/16 0.00
39 ----- ------I--- --------I- ------ 9/14 0.32 37,628
----- ------I--- -----G---- ------ 4/14 0.32.
----- -----AI--- -----G---- ------ 1/14
63 ----- ------I--- -----G---- ------ 5/12 1.17 0.80 0.04 122,968
----- ------I--- -------D-- ------ 3/12 1.17 0.80 0.80
----- ---F--I--- -------D-- ------ 1/12 0.63 0.04 0.80
----- ---F--I--- -----G---- ------ 2/12 0.63 0.04 0.04
----- ---C--I--- -----G---- ------ 1/12
88 ----- ------I--- -----G---- ------ 8/14 0.77 190,263
----- ---F--I--- -----G---- ------ 6/14 0.64
139 ----- ------I--- -----G---- ------ 2/11 256,432
----- ---F--I--- -----G---- ------ 8/11
----- ---F--I--- -----G-K-- ------ 1/11
156 ----- ------I--- -----G---- ------ 1/14 0.77 290,576
----- ---F--I--- -----G---- ------ 13/14 0.53
AEstimated weeks from infection.
BThe Consensus B sequence is given as a reference for amino acid position 71 to 101 of the HIV-1 Gag p17 region. The HLA-A2
restricted epitope SL9 is underlined with a single unbroken line, the HLA-A1 restricted epitope GY9 with a dotted line, and the HLA-B8 restricted epitope EL9 with
double lines.
CThe frequency of each clone is given as a number of the total number of clones sequenced. The major autologous sequence at each time-point is given
in bold face letters.
DThe autologous CTL responses are given for each peptide tested. The at week 63 minor viral sequence, which by week 139 becomes the major
viral sequence, are indicated by a black box. Likewise, the corresponding CTL responses are surrounded by black boxes for each of the HLA-A2-, HLA-A1-, and HLA-B8-
restriced responses, respectively. The viral variant that generates the strongest CD8+ T cell response for every HLA-restriction at each time-point is given in bold.
doi:10.1371/journal.pone.0000225.t005
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Figure 5. Characterization of the HLA-A2-restricted SL9-specific (82I and 79F82I autologous variants) and HLA-A1-restricted GY9 specific CTL
responses in OP428. Peptide titration of the autologous epitope variants was conducted to evaluate the functional avidity of the responses over
time, at weeks 39, 88, and 139 from estimated infection. The CFC assay was used to measure the production of gamma interferon by antigen specific
CD8+ T cells, with the indicated peptides in 10-fold dilutions.
doi:10.1371/journal.pone.0000225.g005
CTL-Driven HIV Evolution
PLoS ONE | www.plosone.org 11 February 2007 | Issue 2 | e225Figure 6. Phylogenetic tree illustrating viral evolution of the HIV-p17 gag region (HXB2 coordinates 790–1431) in subject OP428 under selective
pressure. Positively selected amino acid sites within the HLA-A2 ((SL9,
77SLYNTIATL
85 (patient consensus)), HLA-A1 (GY9,
71GSEELRSLY
79), and HLA-B8
(EL9,
93EVKDTKEAL
101) restricted epitopes. Amino acids corresponding to the consensus B sequence are shown in blue, while the Y79F mutation
within SL9 and GY9 is given in red, and the E93D and V94I mutations within EL9 are shown in green on the tree. The variation found at the positively
selected amino acid position 62, where a potential compensatory mutation (E62A) seems to occur prior to, and associated with, the Y79F substitution
are as follows: variation at position 62: E, blue, G, orange, V purple and A red. Amino acid numbering corresponds to HXB2 Gag. Scale bars signify
substitutions/site. w:corresponds toestimatedweekfrominfection (e.g. a clone named428_w15 was obtained from a plasma sample drawnatweek15).
doi:10.1371/journal.pone.0000225.g006
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PLoS ONE | www.plosone.org 12 February 2007 | Issue 2 | e225avidity of the HLA-A1-restricted GY9 response was lower. Also,
by week 139, when the majority of the viral clones contained the
79F mutation, the magnitude of the response was on the verge of
becoming undetectable indicating that there was no cross-
recognition of the 79F mutant by the GY9-specific CTL response.
Thus, the 79F substitution affects CTL responses against both the
SL9 and especially the GY9 epitopes, and seems to be a potent
CTL escape mutation. Strong positive selection of 79F was
detected using phylogenetic analysis (codeml from PAML) and
supported our functional data [49]. In OP428 the viral load
increased substantially during the period in which the viral
population successfully evaded anti-Gag-specific CTL-responses
restricted by HLA-A1, and A2 and developed a potential
compensatory mutation in position 62 (Table 5, Figure 6).
Selection of the subtype-B consensus sequence
induced by CTLs recognizing mutant epitope
variants
With regard to the responses seen in patient OP428 targeting the
HLA-B8 restricted EL9 epitope (Table 5), we found that 0.8% of
the CTLs were actually directed at the emerging E93D mutant
epitope (
93DVKDTKEAL
101) at week 63, while there was no
recognition of the index sequence,
93EVKDTKEAL
101. The
E93D mutation was only detected in the viral sequences from this
time point and our phylogenetic tree analysis showed that all the
clones, which carried the E93D mutation, clustered together on
a single branch of the tree and did not spread any further,
demonstrating the effectiveness of the CTL response in eliminating
cells infected with these viral variants (Figure 6). An additional
mutation, R91G, is seen upstream of the EL9 epitope and
downstream of the SL9 epitope. While there are no epitopes
described overlapping this position, that OP428 could recognize,
the mutation may affect processing of the EL9 epitope. In OP428
the viral load increased substantially during the period in which
the viral population successfully evaded anti-Gag-specific CTL-
responses restricted by HLA-A1, A2, and B8 (Table 5).
In addition to the multiple targeting of the HIV-Gag p17
region, subject OP428 had a CTL response towards an HLA-A2-
restricted epitope in the RT region of HIV-Pol, RT 33-41
(Table 6). Initially, the major viral population carried an isoleucine
in position three of the epitope,
33ALIEICTEM
41 (35I), while no
subtype B consensus epitope sequences were found. By week 63,
a new variant,
33ALMEICTEM
41 (35M), started to emerge and
became the major viral sequence by week 88. The 35M
substitution did not persist and by week 156 was replaced by
a virus identical to the consensus B sequence
33ALVEICTEM
41,
an example of evolution of the transmitted virus variant toward
the subtype B consensus sequence.
We went on to study what impact the cellular immune response
had on the evolving viral population and determined the CTL
response against the subtype B consensus sequence and the two
patient variants, 35I and 35M at week 88 (Table 6). We found that
the main target was the 35M variant, which was the most frequent
epitope sequence found in the viral population, followed by
a weaker response to the 35I variant, which dominated the
population at weeks 39 and 63. We could only detect negligible
CTL responses directed at the emerging subtype B consensus
epitope. At week 156, the major CTL targets continued to be the
two mutant epitopes, despite the consensus B epitope sequence
being the major viral variant. The phylogenetic analysis showed
strong positive selection at position 35 as the epitope changed from
I to M to V (AKNI, unpublished data). Together with the CTL
response detected against the EL9 epitope in HIV-Gag, this is our
second example of how HIV-1-specific CTL responses directed at
variant epitope sequences can cause the virus epitope to develop
into a consensus B-like sequence.
Increasing magnitudes of HIV-Gag restricted CTL
responses associated with broad CTL responses and
viral escape
We next evaluated the longitudinal cellular immune responses
against two control antigens, a peptide pool consisting of well-
identified HLA class I restricted CMV, EBV and Influenza
epitopes (CEF), and a peptide pool consisting of overlapping 11-
mer peptides spanning the whole HIV-Gag p55 region (Figure 7).
During the study period the overall magnitude of the CTL
responses towards the CEF peptide pool remained stable
(Figure 7A) while the cellular immune responses against HIV-
Gag increased, especially in three patients, OP177 and OP428
and OP583 (Figure 7B). Subjects OP177 and OP428 were also the
only subjects who showed an increase in response against the CEF
peptide pool. Both OP177 and OP428 developed multiple HLA-
A2-restricted CTL responses and showed evidence of viral escape
within targeted epitopes, while OP583 had no detectable HLA-
A2-restricted responses. In OP177 and OP428 the increase in
magnitude of CTL responses against HIV-Gag were associated
with an increased viral load during the first two years, as these
patients had a viral load increase of 1.27 and 1.66 log10,
respectively, compared to 0.31 log10 in OP583. A fourth patient,
OP599, had a high magnitude of HIV-Gag CTL responses at
week 72, while targeting multiple HLA-A2-restricted epitopes, and
these epitopes (including SL9) showed signs of viral evolution.
Table 6. An emerging anti-HIV-Pol mutant-specific CTL
response responsible for selection of the consensus B like
sequence in patient OP428.
......................................................................
Week
A HIV-Pol RT Sequence
B Clones
C
CD8+ T cell
responses
(% IFN-c and TNF-a)
D
28EEKIKALVEICTEMEKEGK
46
39 -------I----------- 15/17 0.00
-------T----------- 1/17 n.a.
-------I-----T----- 1/17 n.a.
63 -------I----------- 13/14 n.a.
-------M----------- 1/14 n.a.
88 -------I----------- 4/12 0.15
-------I----D------ 1/12 n.a.
-------M----------- 5/12 0.34
-------MK---------- 1/12 n.a.
------------------- 1/12 0.01
156 -------I----------- 1/13 0.47
-------M----------- 3/13 0.56
-------M---A------- 1/13 n.a.
------------------- 8/13 0.14
AEstimated weeks from infection.
BThe consensus B sequence spanning amino
acid 28 to 46 in RT is given as a reference with the epitope RT 33-41 given in
bold face letters.
CThe frequency of each clone is given as a number of the
total number of clones sequenced. The major autologous sequence at each
time-point is indicated in bold face numbers.
DThe autologous CTL responses
are given for each peptide tested. The viral variant that generates the
strongest CTL response at each time-point are given in bold.
doi:10.1371/journal.pone.0000225.t006
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PLoS ONE | www.plosone.org 13 February 2007 | Issue 2 | e225DISCUSSION
We have identified different modes of viral adaptation in response
to dynamic fluctuating inter and intra epitopic CTL responses
following primary HIV-1 infection. The continuously developing
CTL responses were detected both against an unchanged viral
population forcing viral evolution to the point of HLA-A2
adaptation, as well as against existing mutants inducing reselection
of a consensus B like viral variant. Broad CTL responses were
directed against epitopes in Gag, Pol, Env, and Nef and developed
in 27% of our patients during the first year of infection and were
associated with the induction of viral escape mutations in targeted
epitopes. We confirmed in two of three subjects with broad
responses that overlapping and flanking CTL responses of
different HLA-restrictions were simultaneously targeting the
HIV-Gag or HIV-Nef region. Surprisingly, while the three
subjects with an early broadening of HLA-restricted HIV-1-
specific CTL responses experienced an increase in viral plasma
load during the first year of infection, the vast majority of our
patients (6/7) who either had no HLA-A2-restricted CTL
responses, or responses towards Gag only (n=2), had stable
plasma RNA levels during this period. While the viral load
increased in the group with broad HLA-A2-restricted CTL
responses, after year one the average viral loads were similar.
This suggests that at least some of the time, broadening CTL
responses can be associated with escape from earlier temporarily
effective immune responses, and can be a footprint left by effective
viral evasion of CTL responses rather than demonstrating immune
control.
In chronic untreated infection, 70-75% of all subjects recognize
the subtype B consensus SL9 sequence [55,56,58] and .90%
recognize one or more of the common variants [61], suggesting
that the development of responses against this epitope, and epitope
variants, is a process that continues beyond the first years of
infection, as only 6/11 recognized this epitope after the first year.
The development of CTL responses was consistently associated
with the induction of viral escape mutations in the targeted
epitopes, which was further linked to the development of novel
CTL responses towards the new epitope variants. This finding
supports the concept of antigenic oscillations and shifting
immunodominance in HIV-1 infection described earlier, based
on phylogenetic analysis of viral sequences [63]. New CTL
responses developed towards epitopes, which had remained
unchanged since primary infection, suggesting that sequential
maturation of the cellular immune responses occurs throughout
this period.
CTL responses towards all HIV-1 genes have generally been
thought to have an inhibitory effect on disease progression,
although responses restricted by certain HLA molecules, e.g. B27,
B57, and B58, are thought to be more efficient than others in
constraining viral replication. Our data, which is one of the most
comprehensive studies of a particular set of HLA-restricted CTL
responses and viral evolution to date, suggest that developing
broad responses against epitopes in Gag, Pol, Env, and Nef, in
association with the development of escape mutations, have
a negligible effect on viral load. As we studied the major HIV gene
sequences, it is possible that there were CTL responses to other
parts of the virus that were not studied and also influenced viral
load. Our observation is supported by data from a study of CTL
responses in a cohort of long-term non-progressors (LTNP) in
whom broad CTL responses were associated with a median viral
load 30 times higher than that found in patients with no CTL
responses and loss of LTNP status within 4 years of study entry
[64]. However, the extended detailed analysis of the impact the
overall CTL responses had on viral evolution in one patient in
early chronic infection (week 158 from primary infection) showed
that several of the amino acid positions under positive selection in
HIV-Nef were not recognized by CTL. Instead, several of these
mutations were associated with reversion towards consensus B like
variants, supporting the notion that some of these mutations may
lower viral fitness [21,33,34,35]. Although we did not directly
measure viral fitness, and thus the fitness cost of the CTL escape
mutations that we identified can not be fully characterized, our
findings suggest that mutations introduced to enhance viral fitness
may compensate for the potential effect developing CTL responses
may have on viral load, pointing out the importance of
understanding these complex interactions to be able to identify
which CTL responses are most advantageous.
The HIV-Nef region has previously been shown to be preferen-
tially targeted in primary HIV-1 infection [65,66]. However, we
found early HLA-A2-restricted anti-Nef-specific CTL responses in
only one of our patients, OP177. Over time, the viral population
Figure 7. Increase of HIV-Gag responses over time. The cellular
immune responses against the control peptide pools CEF (A) and HIV-
Gag (B) were followed in longitudinally drawn PBMC samples. No
statistically significant differences in CTL responses to non-HIV antigens
included in the CEF peptide pool were seen over time (Paired T-test,
p=0.269). However, the increase in CTL response to the HIV-Gag (p55)
peptide pool was borderline significant (Paired T-test, p=0.064). The
responses in subjects OP177, OP428 and OP599, who developed
multiple HLA-A2-restricted CTL responses and showed evidence of viral
escape within targeted epitopes, are indicated with dashed lines.
doi:10.1371/journal.pone.0000225.g007
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amino acid positions 83, 85, 87 and 91. These mutations occurred
both alone, and linked, and after three years the dominant epitope
variant (83G, 85L) was similar to that most frequently found in
both HLA-A2-positive and negative patients in our study as well as
in the database. Thus, in other patients, the CTL escape mutations
we observed develop in OP177, which may have been transmitted,
and persisted after transmission, suggesting a negligible fitness cost.
In the Caucasian population, the HLA-A2 allele is the most
prevalent HLA allele, present in around 46% of all individuals
[67]. It is thus possible that the selective pressure induced by the
HLA-A2-restricted Nef CTL response over time has been shaping
the circulating viral population resulting in the 83G–85L variant
being fixed at the population level. As this epitope has been shown
to be targeted by CTL responses restricted to additional HLA-
alleles, HLA-B60 and Cw*03 [68], these responses may have
contributed to shaping of the viral population. Transmission and
accumulation of CTL escape variants has previously only been
shown in HLA-B57/B5801 positive individuals [21], and epitope
variants selected in this patient group may take longer to
accumulate in the viral population due to the lower prevalence
of HLA-B57 relative to HLA-A2.
HIV p17 Gag contains many regions of overlapping CTL
epitopes restricted by multiple HLA molecules, including the one
carrying the HLA-A1 and HLA-A2-restricted CTL epitopes, GY9
(
71GSEELRSLY
79) and SL9 (
77SLYNTVATL
85). In one patient,
OP428, we found a dynamic interaction and synergy between the
CTL responses towards these two epitopes and viral evolution.
The cumulative responses were responsible for the positive
selection of the dual CTL escape virus variant carrying an Y79F
substitution. The 79F mutation initially reduced the response to
SL9 by approximately 50%, and abolished recognition of GY9. As
the 79F mutation is located in the anchor position of the HLA-A1-
restriced epitope, our finding suggests that the 79F mutation
prohibited binding of GY9 to the HLA-A1 molecule. For the
HLA-A2-restricted SL9 epitope, it was recently described that the
Y79F and V82I mutations affect T cell-receptor contact [61].
While Iversen et al. found that most chronically infected, HLA-A2-
positive patients with evidence of positive selection for escape
mutations in SL9, or fixed escape variants, had lower viral loads
than patients carrying the wild type sequence, we found that
escape mutations within the overlapping GY9 and SL9 epitopes in
our patient in early infection correlated with an increase in viral
load. The difference between our patient and the general trend
may be due to the positive selection of alanine at position 62,
which in combination with the Y79F substitution, propagates very
successfully and dominates the viral population at later time
points. Structural analysis suggested that the side-chain of the
amino acid in position 62 interacts with that of the amino acid in
position 79, and thus may be a compensatory change reducing, or
eliminating, any fitness cost associated with the escape mutation in
SL9. This is supported by the observation that the combination of
62A and 79F is more than five times as common as 62A alone
among the subtype B virus variants in the HIV database (30). The
added viral advantage of escaping both an HLA-A1 and HLA-A2-
restricted immune response may also lead to higher viral loads. It
is likely, that although the changes in our patient conferred
immune evasion, another host may have highly efficient T-cells
able to target the viral variants [61,69,70]. In our subject we
identified development of a high avidity CTL response against the
79F variant epitope after the initial viral load increase. Our results
demonstrate the role CTL responses play in shaping viral
evolution, once more pointing out the importance of understand-
ing the interaction between selective forces induced by CTL and
functional and structural constraints of the virus.
We found two independent examples of potent CTL responses
generated against epitope variants, which resulted in selection of
the subtype B consensus sequence. In the first case an HLA-B8-
restricted CTL response was generated against an emerging
mutant epitope in the HIV p17 Gag region and in the second,
HLA-A2-restricted CTL responses targeted sequential epitope
variants in reverse trancriptase of HIV-Pol. Although the
generation of de novo escape-variant-specific CTL responses has
been described in chronic HIV-1 infection [71], this is the first
example of rapid development of potent responses in early
infection. While the SL9-specific CTL responses arose against
epitope sequences that had remained constant since primary
infection, other responses can develop against a changing viral
population.
Our data is in line with the notion of HLA adaptation [29,31].
It is thought that viral evolution is the result of a trade-off between
the benefit of escaping CTL responses and the impact of CTL
escape mutations on viral fitness [69]. Efficient variant-specific
CTL responses to several epitopes restricted by HLA-A2, HLA-
B8, and HLA-B15 in our study indicate that some very common
epitope sequences previously have been adapted by a potent CTL
response. This notion is supported by the fact that after sexual
transmission, viral CTL escape mutations may be retained [72]
and reversion of the mutations can be very slow, or non-existent
[21]. Thus, selection and preservation of certain amino acids
within CTL epitopes in the HIV-genome may not only be
dependent on functional or structural constraints but also on how
well they are recognized by effective CTL responses.
Our data reinforce the concept that not all CTL responses are
equally beneficial to the patients and some represent immunolog-
ical footprints of earlier effective immune responses from which
the virus has escaped. Our results showed a greater increase in
viral plasma load during the first year of infection in subjects who
developed early broad HLA-restricted responses in association
with viral escape than in subjects with no or narrow HLA-A2-
responses towards the SL9 epitope in p17 Gag only. Thus,
therapeutic vaccination with different CTL epitope antigens
should only target epitopes clearly associated with containment
of viral load or possibly in areas where CTL escape mutations are
associated with substantial viral fitness costs.
SUPPORTING INFORMATION
Table S1 Primer sequences
Found at: doi:10.1371/journal.pone.0000225.s001 (0.03 MB
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